Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Unresectable Locally Advanced NSCLC
Interventions
DRUG

Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta

"Cisplatin 75 mg/m2 day 1 and 22~Etoposide 80mg/m2 days 1-3, 22-24~Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)~Filgrastim 5µg/kg\* SQ injection days 4-13 and days 25-34~Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles~Pegfilgrastim 6 mg SQ injection day 2 of each cycle"

Trial Locations (1)

33140

Mount Sinai Medical Center, Miami Beach

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Mt. Sinai Medical Center, Miami

OTHER

NCT00682383 - Combined Modality Therapy With Growth Factor Support in Locally Advanced Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter